Navigation Links
Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
Date:5/15/2013

BOULDER, Colo., May 15, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, MEK162 (licensed to Novartis) and selumetinib (licensed to AstraZeneca) at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 – June 4, 2013 in Chicago, Illinois.  Both MEK inhibitors are expected to advance into Phase 3 trials in 2013:  Novartis expects to evaluate MEK162 in NRAS- and BRAF-mutant melanoma and Array expects to evaluate MEK162 in low-grade serous ovarian cancer.  In addition, AstraZeneca expects to begin Phase 3 or pivotal registration trials with selumetinib in non-small cell lung cancer and thyroid cancer. 

The following is a summary of the presentations that will be given at ASCO:  ORAL PRESENTATIONSTitle:Phase II study of selumetinib versus temozolomide in gnaq/Gna11 mutant uveal melanoma (Abstract # CRA9003)Final results will be presented at ASCO.Presenter: Richard D. Carvajal, MDDate:Saturday, June 1, 2:15-2:30 p.m. CDT (Oral Presentation)Embargo:ASCO's embargo for this abstract will lift on Saturday, June 1 at 6:30 a.m. CDT.Press Conference ASCO will feature this study in the 2013 ASCO Annual Meeting press program on Saturday, June 1 from 8 – 9 a.m. CDT.Title: 

Phase II double-blind, randomized study of selumetinib plus dacarbazine versus placebo plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma (Abstract # 9004)Presenter: Mark R. Middleton, PhD, FRCPDate: 

Saturday, June 1, 2:30-2:45 p.m. CDT POSTER PRESENTATIONSTitle: Preliminary results from a Phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-depe
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
2. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
3. New Versa HD System Tops Elektas Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum
4. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
5. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
6. Array BioPharma To Present At The Cowen Annual Health Care Conference
7. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
9. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
10. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
11. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015 According to a ... by Product (Natural & Synthetic, Fibrin, Collagen, Gelatin, Cyanoacrylate, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... reach $2.64 Billion by 2020, growing at a CAGR ... Browse 119 market T ables ...
(Date:7/1/2015)... July 1, 2015 Prismic Pharmaceuticals, Inc., a ... medical foods, today announced the election of Joseph ... to its Board of Directors. Commenting on ... Peter Moriarty , Chairman and CEO of Prismic, stated, ... Martin Simonetti have accepted our invitation to ...
(Date:7/1/2015)... , July 1, 2015 Dynatronics ... manufacturer and marketer of rehabilitation and physical therapy ... $4,025,000 private placement financing led by affiliates of ... equity investor focused on the healthcare industry. The ... organic growth and pursue potential strategic acquisitions.  ...
Breaking Medicine Technology:Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 2Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 3Surgical Sealants and Adhesives Market Worth $2.64 Billion by 2020 4Joseph Krivulka and Martin Simonetti Join Board of Prismic Pharmaceuticals 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 3
... , HELSINKI, Dec. 14 Cancer patients in Finland ... of RapidArc® radiotherapy technology from Varian Medical Systems (NYSE: ... the Nordic region. Clinicians at Docrates Clinic in Helsinki are ... patients with multiple brain metastases and cancers of the abdomen ...
... , WALTHAM, Mass., Dec. 14 According to ... market intelligence, increased use of safety devices for small-bore connectors ... of the enteral feeding device markets in both the US ... Enteral Feeding Devices 2010 report finds that the giving ...
Cached Medicine Technology:Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Did you ... June is Men’s Health Month, and we at Advanced Fertility Center of Texas (AFCT) ... in men. , While infertility is often considered to be a “woman’s issue,” ...
(Date:7/1/2015)... ... July 01, 2015 , ... Convoy of Hope will partner ... Twin Cities on Saturday, August 1, at Spring Lake Park High School. , During ... than $1 million worth of goods and services including free food, health services, family ...
(Date:7/1/2015)... Orange, NJ (PRWEB) , ... July 01, 2015 , ... Scoliosis is a disorder in ... the National Scoliosis Foundation, it affects 2 to 3 percent of the population, or an ... scoliosis most often develops in children between the ages of 10 and 15. Most types ...
(Date:7/1/2015)... ... July 01, 2015 , ... A ... just published a top ten list they hope will guide future mesothelioma research. ... to read it now. , More than 450 mesothelioma patients, caregivers, ...
(Date:7/1/2015)... ... , ... B. E. Smith, the only full-service leadership solutions firm dedicated exclusively ... recruitment for Capital Health in Pennington, N.J. One of the top ... placed more than 1,000 healthcare executives into organizations. , Capital Health is a ...
Breaking Medicine News(10 mins):Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... It has been reported that bacteria lurking in ... called endotoxins that may trigger asthma and asthma-related ... association has been established between endotoxin levels and ... medication use, and wheezing. These relationships were strongest ...
... says that a combination of newer drugs for ... ,Hypertension is the most important preventable cause of ... of anti-hypertensive drugs for prevention of cardiovascular mortality ... trial using standard diuretic or Beta-blocker therapy, or ...
... report published by the Department of Veterans Affairs (VA) ... levels and provided a guideline to do so.// ... heart and blood vessels, but they may also increase ... Alzheimer’s disease. ,During September, celebrating the National Cholesterol ...
... acid as found to reduce the rate of birth defects. ... found that more than one third of birth defects are ... Spina bifida and anencephaly, known as neural-tube defects, arise when ... close during the first weeks of pregnancy. The defect causes ...
... the current edition of Pediatrics that use of alcohol based ... gastro-intestinal infections.// ,In a study of 292 Greater Boston ... those that used the gel had a 59 percent reduction ... day care centers, and all had a least one child ...
... from the Stanford University School of Medicine have reported the ... result of the study has found that //high doses of ... growth of cancer in patients with prostate cancer. The study ... the growth of prostate cancer by 70 percent. ...
Cached Medicine News:Health News:Is your house safe enough to protect against asthma attacks? 2Health News:High Cholesterol Can Be Controlled By Screening And Prevention 2Health News:Folic acid enriched grain reduces birth defects 2Health News:Less Stomach Infections If Hand Sanitizer Gel Is Used 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: